ATE445015T1 - Verfahren zur herstellung rekombinanter, lipid- modifizierter psaa proteine und deren verwendung - Google Patents

Verfahren zur herstellung rekombinanter, lipid- modifizierter psaa proteine und deren verwendung

Info

Publication number
ATE445015T1
ATE445015T1 AT99903011T AT99903011T ATE445015T1 AT E445015 T1 ATE445015 T1 AT E445015T1 AT 99903011 T AT99903011 T AT 99903011T AT 99903011 T AT99903011 T AT 99903011T AT E445015 T1 ATE445015 T1 AT E445015T1
Authority
AT
Austria
Prior art keywords
proteins
psaa
psaa proteins
lipidated psaa
lipid
Prior art date
Application number
AT99903011T
Other languages
English (en)
Inventor
Edwin Ades
George Carlone
Barun De
Jacquelyn Sampson
Robert Huebner
Original Assignee
Ct Disease Contr & Prevention
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Disease Contr & Prevention filed Critical Ct Disease Contr & Prevention
Application granted granted Critical
Publication of ATE445015T1 publication Critical patent/ATE445015T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99903011T 1998-02-03 1999-01-14 Verfahren zur herstellung rekombinanter, lipid- modifizierter psaa proteine und deren verwendung ATE445015T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1778298A 1998-02-03 1998-02-03
PCT/US1999/000379 WO1999040200A1 (en) 1998-02-03 1999-01-14 RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE

Publications (1)

Publication Number Publication Date
ATE445015T1 true ATE445015T1 (de) 2009-10-15

Family

ID=21784518

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903011T ATE445015T1 (de) 1998-02-03 1999-01-14 Verfahren zur herstellung rekombinanter, lipid- modifizierter psaa proteine und deren verwendung

Country Status (13)

Country Link
US (2) US7635486B1 (de)
EP (1) EP1053329B1 (de)
JP (1) JP4290875B2 (de)
AT (1) ATE445015T1 (de)
AU (1) AU2313199A (de)
BR (1) BR9909097A (de)
CA (1) CA2319404C (de)
DE (1) DE69941505D1 (de)
DK (1) DK1053329T3 (de)
ES (1) ES2334185T3 (de)
NZ (1) NZ525674A (de)
PT (1) PT1053329E (de)
WO (1) WO1999040200A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
AU7193501A (en) * 2000-07-10 2002-01-21 Us Health Multiple antigenic peptides immunogenic against streptococcus pneumoniae
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
KR20060019515A (ko) * 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (de) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
CN103773779B (zh) * 2013-12-31 2017-02-15 李越希 化学合成肺炎链球菌表面粘附素a的基因片段及表达、应用
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3008042A1 (en) 2015-12-10 2017-06-15 National Research Council Of Canada Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010238A1 (en) * 1991-11-14 1993-05-27 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Pneumococcal fimbrial protein a vaccines
AU721954B2 (en) * 1995-06-07 2000-07-20 Connaught Laboratories Inc. Expression of lipoproteins
US6924112B1 (en) 1997-12-04 2005-08-02 Biomethodes S.A.R.L. Cloning method by multiple-digestion, vectors for implementing same and applications
NO983911D0 (no) 1998-08-26 1998-08-26 Norsk Hydro As Alginatkapsler til bruk ved behandling av hjernesvulst

Also Published As

Publication number Publication date
AU2313199A (en) 1999-08-23
CA2319404C (en) 2014-01-07
US7960535B2 (en) 2011-06-14
JP4290875B2 (ja) 2009-07-08
WO1999040200A1 (en) 1999-08-12
US7635486B1 (en) 2009-12-22
ES2334185T3 (es) 2010-03-05
EP1053329A1 (de) 2000-11-22
DE69941505D1 (de) 2009-11-19
PT1053329E (pt) 2010-01-04
EP1053329B1 (de) 2009-10-07
JP2002505083A (ja) 2002-02-19
DK1053329T3 (da) 2010-01-25
CA2319404A1 (en) 1999-08-12
US20100260802A1 (en) 2010-10-14
BR9909097A (pt) 2000-12-05
NZ525674A (en) 2005-01-28

Similar Documents

Publication Publication Date Title
ATE445015T1 (de) Verfahren zur herstellung rekombinanter, lipid- modifizierter psaa proteine und deren verwendung
EP1559795A3 (de) Genomische Sequenzen von Neisseria und Verfahren zu ihrer Verwendung
MXPA01011047A (es) Secuencias genomicas de neisseria y metodos para su uso.
EP1584685A3 (de) Tumorassoziierte Antigenderivate der Mage-Familie, Nukleinsäuresequenzen, die dafür kodieren, zur Herstellung von Fusionsproteinen und Zusammensetzungen zur Impfung
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
PL366826A1 (en) Reducing the immunogenicity of fusion proteins
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
WO2005071088A3 (en) Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
WO2002032962A3 (en) Compositions of human proteins and method of use thereof
EP2275552A3 (de) Antigenpeptide aius Neisseria
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DE3853454D1 (de) Therapeutische Zusammensetzungen gegen Streptokokken-Infektionen, transformierte Wirte, Verfahren zur Immunisierung und gentechnologisch hergestellte Produkte.
CA2171611A1 (en) Analog of haemophilus hin47 with reduced protease activity
DE59101580D1 (de) Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
DE69408135D1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
DK0892054T3 (da) Clostridium perfringens-vaccine
GB9205704D0 (en) High molecular weight membrane proteins of non-typeable haemophilus
WO2002020038A3 (en) Method for down-regulating ige
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE421331T1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
HUT51332A (en) Process for expressing p.falciparum cirkumsporozoita protein by yeast
DK0500576T3 (da) Ydre membranprotein P1 og peptider fra Haemophilus inluenzae type b
DE60139952D1 (de) Immunogene glycopeptide. screening- und herstellungsverfahren sowie verwendungen
WO2003077843A3 (en) Methods for purifying selected cea family member proteins
CA2347278A1 (en) Vaccine based on attenuated haemophilus somnus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053329

Country of ref document: EP